|本期目录/Table of Contents|

[1]罗助荣,林 毅,张克己,等.福建地区汉族人群骨保护素基因rs2073617T/C多态性与急性冠脉综合征病变程度的关系[J].医学研究与战创伤救治(原医学研究生学报),2011,13(05):385-388.
　LUO Zhu-rong,LIN Yi,ZHANG Ke-ji,et al.Correlation between osteoprotegerin gene rs2073617T/C polymorphism and severity of acute coronary syndromes in Fujian area[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2011,13(05):385-388.
点击复制

福建地区汉族人群骨保护素基因rs2073617T/C多态性与急性冠脉综合征病变程度的关系()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第13卷
期数:
2011年05期
页码:
385-388
栏目:
出版日期:
2011-09-20

文章信息/Info

Title:
Correlation between osteoprotegerin gene rs2073617T/C polymorphism and severity of acute coronary syndromes in Fujian area
文章编号:
1672-271X(2011)05-0385-04
作者:
罗助荣; 林 毅; 张克己; 郑磊磊; 徐高阳
350025 福建福州，南京军区福州总医院心内科
Author(s):
LUO Zhu-rong; LIN Yi; ZHANG Ke-ji; ZHENG Lei-lei; XU Gao-yang
Cardiology Department,Fuzhou General Hospital of Nanjing Military Command,Fuzhou,Fujian 350025，China
关键词:
骨保护素; 急性冠脉综合征; 多态性; DNA测序
Keywords:
osteoprotegerin;  acute coronary syndrome;  gene polymorphism;  DNA sequences
分类号:
R541.4
DOI:
-
文献标志码:
A
摘要:
目的 探讨福建地区骨保护素(osteoprotegerin，OPG)基因启动子rs2073617T/C位点基因多态性与急性冠脉综合征(acute coronary syndrome，ACS)病变程度的关系。方法 采用多聚合酶链式反应-限制性片段长度多态性(PCR-RFLP)技术检测360例ACS患者和120例正常对照者OPG基因rs2073617T/C多态性位点基因型，同时采用DNA测序对酶切产物进行鉴定，并比较其与ACS及其病变枝数和冠状动脉积分的关系。结果 OPG基因rs2073617T/C多态性TC、TT、CC三种基因型在ACS组和对照组中的频率分别为43.3%、33.3%和23.3%，以及47.7%、26.7%和25.6%;两组比较差异无统计学意义(P>0.05)；ACS患者冠状动脉单枝、双枝、多枝病变组间OPG基因rs2073617T/C基因型频率差异无统计学意义(P均>0.05)。结论 OPG基因rs2073617T/C多态性与福建地区汉族人群中ACS的发生及冠状动脉病变程度无相关性。
Abstract:
Objective To detect the association of osteoprotegerin gene rs2073617T/C polymorphisms with severity of acute coronary syndrome(ACS) in Fujian area. Methods The polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) was used to detect OPG gene rs2073617T/C in three hundred and sixty patients with ACS (cases group) and 120 matched control group. DNA sequences of enzyme digested products were also analyzed. Results The frequencies of TC,TT and CC types of OPG rs2073617T/C polymorphism in ACS patients and controls were 43.3%,33.3% and 23.3% VS 47.7%,26.7% and 25.6%. There was no significant difference in the distribution frequency of three genotypes and two alleles of OPG rs2073617T/C between the ACS and control groups (P>0．05). OPG gene rs2073617T/C in all lesions was no difference among the groups(P>0．05). Conclusion OPG gene polymorphism was existing in Hans population of Fujian Han,and have no association with acute coronary syndrome and severity of ACS in Han nationality of Fujian.

参考文献/References:

[1]罗助荣.骨保护素系统与动脉粥样硬化的研究进展[J].东南国防医药，2010，12(6):523-525.
[2]中华医学会心血管病学分会.不稳定型心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志，2007,35(4):295-304.
[3]Antman EM,Armstrong PW,Bates ER,et al.2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction[J].JACC,2008,51(2):210-247.
[4]Sirnonet WS，Laeey DL，Dunstan CR，et al．Osteoprotegerin:a novel seelated protein involved in the regulation of bone density[J]．Cell，1997,89(2):309-319．
[5]Tsuda E，Goto M，lVlochizuki S，et al．Isolation of a novel cytokinefrom hurmn fibroblasts that specifically inhibits osteoclastogenesis[J]．Bioehem Biophys Res Contain，1997，234(1):137-142．
[6]Palazzuoli A,Ascione R,GallottaM,et al.Osteoprotegerin and B-type natriuretic peptide in acute coronary syndromes with preserved systolic function:relationto coronary artery disease extension[J].Int J Cardiol,2009,137(3):295-298.
[7]Omland T,Ueland T,Jansson AM,et al.Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes[J].J Am Coll Cardiol，2008,51(3):627-633.
[8]Hofbauer LC，Schoppet M.Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease [J].JACC,2002,87(9):4078-4079.
[9]Ohmori R，Momiyama Y，Taniguehi H，et al．Association between osteoprotegerin gene polymorphism and coronary artery disease in Japanese men[J]． Atherosclerosis，2006，187(1):215-217．
[10]Soufi M，Schoppet M，Sattler AM，et al．Osteoprotegerin gene polymorphisms in men with coronary artery disease[J]． Clin Endocrinol Metab，2004，89(8):3764-3768．

相似文献/References:

[1]丁雪燕,罗助荣.急性冠脉综合征血清脑钠肽水平及 阿托伐他汀对其影响[J].医学研究与战创伤救治(原医学研究生学报),2009,11(01):37.
　DING Xue-yan,LUO Zhu-rong.Levels of pro-B-type natriuretic peptide in patients with acute coronary syndrome and the effect of atorvastatin on them[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(05):37.
[2]陈丽萍,陈 岩,张 强,等.瑞舒伐他汀序贯治疗对急性冠脉综合征患者血清缺血修饰清蛋白、C反应蛋白、髓过氧化物酶的影响[J].医学研究与战创伤救治(原医学研究生学报),2015,17(03):272.[doi:10.3969/j.issn.1672-271X.2015.03.015]
　CHEN Li-ping,CHEN Yan,ZHANG Qiang,et al.Rosuvastatin sequential therapy impact on IMA， CRP， MPO of patients with acute coronary syndrome[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(05):272.[doi:10.3969/j.issn.1672-271X.2015.03.015]
[3]王苏梦,吴 嘉,牛冬梅,等.急性冠脉综合征患者NT-proBNP、RDW和CRP的水平及相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(04):362.[doi:10.3969/j.issn.1672-271X.2015.04.008]
　WANG Su-meng,WU Jia,NIU Dong-mei,et al.Study of plasma level of NT-proBNP, CRP and RDW in acute coronary syndrome patients[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(05):362.[doi:10.3969/j.issn.1672-271X.2015.04.008]
[4]罗助荣.骨保护素系统与动脉粥样硬化的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2010,12(06):523.

备注/Memo

备注/Memo:
南京军区医学科技创新项目资助(09MA094)
更新日期/Last Update: 2011-09-20